HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acinetobacter lwoffii an emerging pathogen in neonatal ICU.

AbstractBACKGROUND:
Acinetobacter species are ubiquitous in the environment and are important causative agent for nososcomial infection especially in immunocompromised patients. Multi drug resistant Acinetobacter lwoffii are emerging as a pathogen in neoanatal sepsis.
AIMS AND OBJECTIVE:
This study was aimed to evaluate the clinical and antibiotic profile of Acinetobacter lwoffii.
MATERIAL AND METHODS:
This study was done on blood samples from neonates admitted to neonatal intensive care unit during a period of one year from January to December 2012, who developed Acinetobacter infection. The diagnosis of isolates and antibiotic susceptibility testing was done by both conventional as well as by automated system.
RESULTS:
Out of total 13,133 blood samples received for culture, 1418(10.8%) were from NICU. Ninety (6.3%) isolates were found to be positive for the growth of Acinetobacter species. Of these isolates 31.11% were found to be Acinetobacter lwoffii, 68.9% were Acinetobacter baumannii calcaetius complex. Acinetobacter lwoffii isolates were most commonly sensitive to imepenem 16(57%), cotrimoxazole 9(32%), ciprofloxacin 6(21%) followed by amoxyclavulanic acid 2(7%) and cefuroxime 1(3.5%).
CONCLUSION:
Multi drug resistant Acinetobacter lwoffii infection is increasing particularly in premature and very low-birth weight neonates. Judicious and timely antibiotic use in NICUs are one of the important key in controlling multi-drug resistant Acinetobacter infection and improving clinical outcome.
AuthorsSeema Mittal, Madhu Sharma, Aparna Yadav, Kiran Bala, Uma Chaudhary
JournalInfectious disorders drug targets (Infect Disord Drug Targets) Vol. 15 Issue 3 Pg. 184-8 ( 2015) ISSN: 2212-3989 [Electronic] United Arab Emirates
PMID26307173 (Publication Type: Journal Article)
Chemical References
  • Anti-Bacterial Agents
Topics
  • Acinetobacter (drug effects, isolation & purification, pathogenicity)
  • Acinetobacter Infections (diagnosis, epidemiology, microbiology)
  • Acinetobacter baumannii (drug effects, isolation & purification)
  • Anti-Bacterial Agents (pharmacology)
  • Blood (microbiology)
  • Child
  • Communicable Diseases, Emerging (diagnosis, microbiology)
  • Cross Infection (drug therapy)
  • Drug Resistance, Multiple, Bacterial
  • Humans
  • India (epidemiology)
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Male
  • Microbial Sensitivity Tests
  • Sepsis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: